Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9

EO9 is a synthetic indoloquinone which was designed to undergo redox cycling and formation of alkylating intermediates under bioreductive conditions. As part of a phase I clinical trial, EO9 plasma disposition was evaluated in 20 patients receiving 2.7–15 mg/m 2 i.v. weekly for 3 weeks. Pharmacokine...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 1996-08, Vol.32 (9), p.1518-1522
Hauptverfasser:	McLeod, H.L., Graham, M.A., Aamdal, S., Setanoians, A., Groot, Y., Lund, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences bioreductive agents Chemotherapy EO9 limited sampling methods Medical sciences pharmacokinetics Pharmacology. Drug treatments phase I
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!